About the Serum Urate as a Clinically Valid Surrogate in Gout Working Group
Gout is caused by an increase in blood uric acid levels that leads to deposition of uric acid crystals in the joints. These crystals can cause gout flares which manifest as severely painful swollen joints. There are two general treatment strategies, firstly to treat gout flares and secondly to lower the blood uric acid levels in order to prevent the flares from occurring in the first place. It is recommended that a certain level of uric acid in the blood is reached (<0.36mmol/l; 6mg/dl) and that if this is sustained over time the gout flares will reduce and eventually stop. The strength of this relationship between lowering blood uric acid levels and reducing gout flares is the main focus of this working group

Robin Christensen
Co-Chair

Jasvinder A. Singh
Co-Chair

Lisa Stamp
Co-Chair

Melanie Morillon
Fellow
Metter Birthe Pedersen
Patient Research Partner
OMERACT 2020 Virtual Serum Urate Special Interest Group Session
Working Group Publications
Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group
Serum urate as surrogate endpoint forflares in people with gout:A systematic review and meta-regression analysis
Serum Urate as a Soluble Biomarker in ChronicGout—Evidence that Serum Urate Fulfills theOMERACT Validation Criteria for Soluble Biomarkers
Working Group Members:
Lisa Stamp
Jas Singh
Robin Christensen
Metter Birthe Pedersen
Martin Kennedy
Melanie Morillon
Lee Simon
Edoardo Cipolletta
Jayne, David
Kermani, Tanaz
Langford, Carol
Lanier, Georgia
Mackie, Sarah
Mahr, Alfred
Meara, Alexa
Milman, Nataliya
Ozguler, Yesim
Pagnoux, Christian
Robson, Joanna
Shea, Beverly
Tómasson, Gunnar
Merkel, Peter
Milman, Nataliya
Monti, Sara
Quinn, Kaitlin
Tugwell, Peter